After a difficult 2025, Medilines Distributors (PSE: MEDIC) may finally be showing signs of a turnaround.
The company reported first-quarter 2026 revenues of ₱580.6 million, up nearly 35 percent from ₱430.0 million a year earlier. Net income climbed to ₱69.0 million from ₱37.6 million, while operating profit rose to ₱93.0 million from ₱59.3 million. Gross margins also improved slightly to 24 percent.
At first glance, the results suggest a company that may have successfully emerged from one of its more challenging periods.
But a closer look at the financial statements and notes reveals a more interesting story.
The question may no longer be whether Medilines can grow revenue again.
The bigger question is whether the company can finally turn its large receivables and contract assets into consistent cash flow.
A Difficult 2025 May Be Giving Way to Recovery
The latest results are particularly notable because they follow a sharp decline in 2025.
For the full year, revenues fell to ₱1.24 billion from ₱1.45 billion in 2024. Net income dropped to just ₱39.4 million from ₱142.0 million a year earlier, while operating profit declined from ₱186.4 million to ₱63.4 million.
Against that backdrop, the strong first-quarter rebound suggests business activity may be stabilizing.
In fact, first-quarter 2026 net income of ₱69.0 million already exceeded the company’s entire net income for full-year 2025.
This alone makes the latest quarter worth paying attention to.
The Balance Sheet Is Quietly Improving
One of the most encouraging developments appears on the balance sheet.
Notes payable declined from ₱309 million at the end of 2025 to only ₱132.5 million by March 2026.
At the same time, total liabilities fell from ₱908.4 million to ₱983.7 million despite continued business growth. Equity meanwhile increased to approximately ₱2.35 billion.
This matters because Medilines spent much of the past several years managing working-capital requirements associated with large healthcare equipment projects.
Lower debt reduces financing risk while simultaneously improving future profitability through lower interest expense.
The company also generated positive operating cash flow of approximately ₱72 million during the first quarter of 2026.
For investors, that may be one of the most important figures in the entire report.
The Real Story Is Cash Conversion
While the income statement shows recovery, the balance sheet reveals what investors should monitor most closely.
As of March 2026, trade and other receivables stood at approximately ₱2.26 billion. To put that into perspective, receivables remain nearly four times larger than quarterly revenues.
The company’s contract assets also remain substantial at roughly ₱409 million.
These figures are not necessarily problematic by themselves. Medical equipment projects often involve long collection cycles, milestone payments, and government procurement processes. However, they highlight a reality that investors cannot ignore.
The market may ultimately place greater value on the company’s ability to convert receivables into cash than on reported revenue growth alone.
Why The Auditor Paid Special Attention to Revenue
One particularly interesting disclosure appears in the independent auditor’s report.
Revenue recognition was identified as a key audit matter. The auditor specifically highlighted revenue from medical equipment sales, preventive maintenance services, and installation projects. The report also noted that revenue from government agencies accounted for approximately ₱1.11 billion during 2025.
The issue is not that the auditor found wrongdoing.
Rather, the nature of these projects requires judgment regarding
contract performance, project completion, percentage-of-completion calculations, and timing of revenue recognition.
This becomes particularly relevant because the company also disclosed prior-period adjustments involving the timing of revenue and related project costs. Management determined that certain revenues and expenses should have been recognized in earlier reporting periods based on project progress.
While the adjustments were described as timing-related, they reinforce why investors should pay close attention not only to earnings but also to cash flow.
A Potential Re-Rating Opportunity
The encouraging aspect is that some of the indicators investors have long wanted to see are finally beginning to emerge.
Contract assets have fallen significantly from levels reported in prior years. Operating cash flow turned strongly positive in 2025 and remained positive in the first quarter of 2026. Debt has been reduced materially. Profitability has improved.
If these trends continue, the market may eventually begin viewing Medilines less as a company with working-capital challenges and more as a healthcare distribution business generating sustainable cash flow.
Because companies rarely receive higher valuation multiples simply for reporting earnings. They receive higher valuation multiples when investors gain confidence that those earnings can consistently be converted into cash.
The Real Test Is Still Collections
The encouraging aspect is that several indicators have improved. Operating cash flow turned positive in 2025 and remained positive in the first quarter of 2026. Debt declined materially, profitability recovered, and contract assets continued to fall.
Yet the company’s receivables still stand at more than ₱2 billion, while revenue recognition and contract execution remain areas that require significant judgment.
For that reason, the most important measure of Medilines’ progress may not be revenue growth alone, but its ability to convert receivables and contract assets into cash. The latest results suggest improvement, but whether that trend can be sustained remains one of the key questions investors should continue to monitor.
